Amicus Therapeutics Files 8-K on Financials
Ticker: FOLD · Form: 8-K · Filed: May 9, 2024 · CIK: 1178879
| Field | Detail |
|---|---|
| Company | Amicus Therapeutics, Inc. (FOLD) |
| Form Type | 8-K |
| Filed Date | May 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
Amicus Therapeutics filed an 8-K, expect financial updates soon.
AI Summary
On May 9, 2024, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Amicus Therapeutics is providing updates on its financial performance and condition to the SEC, which is crucial for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial condition and results of operations, without immediate news of significant events.
Key Players & Entities
- Amicus Therapeutics, Inc. (company) — Registrant
- May 9, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Amicus Therapeutics?
The primary purpose of this 8-K filing is to report on Amicus Therapeutics, Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 9, 2024.
What is the state of incorporation for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Amicus Therapeutics, Inc.?
The principal executive offices are located at 47 Hulfish Street, Princeton, New Jersey 08542.
What is the telephone number for Amicus Therapeutics, Inc.'s principal executive offices?
The telephone number is 609-662-2000.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-09 07:00:28
Key Financial Figures
- $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar
Filing Documents
- tm2413954d1_8k.htm (8-K) — 25KB
- tm2413954d1_ex99-1.htm (EX-99.1) — 115KB
- tm2413954d1_ex99-2.htm (EX-99.2) — 35KB
- tm2413954d1_ex99-1img001.jpg (GRAPHIC) — 9KB
- tm2413954d1_ex99-2imgg001.jpg (GRAPHIC) — 156KB
- tm2413954d1_ex99-2imgg002.jpg (GRAPHIC) — 396KB
- tm2413954d1_ex99-2imgg003.jpg (GRAPHIC) — 159KB
- tm2413954d1_ex99-2imgg004.jpg (GRAPHIC) — 127KB
- tm2413954d1_ex99-2imgg005.jpg (GRAPHIC) — 116KB
- tm2413954d1_ex99-2imgg006.jpg (GRAPHIC) — 153KB
- tm2413954d1_ex99-2imgg007.jpg (GRAPHIC) — 143KB
- tm2413954d1_ex99-2imgg008.jpg (GRAPHIC) — 169KB
- tm2413954d1_ex99-2imgg009.jpg (GRAPHIC) — 99KB
- tm2413954d1_ex99-2imgg010.jpg (GRAPHIC) — 116KB
- tm2413954d1_ex99-2imgg011.jpg (GRAPHIC) — 146KB
- tm2413954d1_ex99-2imgg012.jpg (GRAPHIC) — 170KB
- tm2413954d1_ex99-2imgg013.jpg (GRAPHIC) — 129KB
- tm2413954d1_ex99-2imgg014.jpg (GRAPHIC) — 131KB
- tm2413954d1_ex99-2imgg015.jpg (GRAPHIC) — 95KB
- tm2413954d1_ex99-2imgg016.jpg (GRAPHIC) — 127KB
- tm2413954d1_ex99-2imgg017.jpg (GRAPHIC) — 216KB
- tm2413954d1_ex99-2imgg018.jpg (GRAPHIC) — 122KB
- tm2413954d1_ex99-2imgg019.jpg (GRAPHIC) — 87KB
- tm2413954d1_ex99-2imgg020.jpg (GRAPHIC) — 76KB
- tm2413954d1_ex99-2imgg021.jpg (GRAPHIC) — 235KB
- tm2413954d1_ex99-2imgg022.jpg (GRAPHIC) — 108KB
- tm2413954d1_ex99-2imgg023.jpg (GRAPHIC) — 160KB
- 0001104659-24-059089.txt ( ) — 5118KB
- fold-20240509.xsd (EX-101.SCH) — 3KB
- fold-20240509_lab.xml (EX-101.LAB) — 33KB
- fold-20240509_pre.xml (EX-101.PRE) — 22KB
- tm2413954d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On May 9, 2024, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on May 9, 2024 to discuss its first quarter results of operations. A copy of the conference call presentation materials is attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated May 9, 2024 99.2 May 9, 2024 Conference Call Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: May 9, 2024 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary